益生菌制剂治疗肠易激综合征的Meta分析

被引：24

作者：

胡玥

陶丽媛

吕宾

机构：

[1] 浙江中医药大学附属第一医院消化科

来源：

中华内科杂志 | 2015年 / 05期

关键词：

肠易激综合征; Meta分析; 益生菌制剂;

D O I：

暂无

中图分类号：

R574.4 [肠道功能紊乱];

学科分类号：

100201 [内科学];

摘要：

目的采用Meta分析评价益生菌制剂对肠易激综合征(IBS)的临床疗效。方法计算机检索PubMed、Cochrane Library、Embase、中国期刊全文数据库、中国生物医学文献数据库、万方数据库中关于益生菌制剂治疗IBS的RCT研究报道。文献检索时限均从建库至2014年8月31日。由两名评价人员按照Cochrane系统评价手册5.1.0标准独立筛选文献、提取资料和评价纳入的文献质量并交叉核对后, 使用RevMan5.20软件对数据进行Meta分析。结果共纳入17项RCT, 1 700例患者。Meta分析结果显示:益生菌与安慰剂相比, 在改善IBS总体症状(SMD=–0.20, 95%CI –0.33～–0.07, P=0.002)、腹痛/腹部不适(SMD=–0.19, 95%CI –0.29～–0.09, P<0.001)、腹胀(SMD=–0.16, 95%CI –0.28～–0.03, P=0.020)、排便不适(SMD=–0.22, 95%CI –0.42～–0.02, P=0.030)方面, 两组差异均有统计学意义。但在总体生命质量评价(SMD=–0.08, 95%CI –0.07～0.23, P=0.290)及不良反应(RR=1.08, 95%CI 0.79～1.49, P=0.630)方面, 两组间差异无统计学意义。结论益生菌制剂能改善患者IBS症状, 具有一定临床疗效, 且不良反应小, 安全性好, 但由于存在偏倚, 仍需更多大规模、多中心、统一结局指标的临床RCT研究, 进一步明确有效菌株, 规范其用法、用量及疗程。

引用

共 20 条

[1]

Clinical trial:Lactobacillus plantarum 299v(DSM 9843)improves symptoms of irritable bowel syndrome[J] Philippe Ducrotté;Prabha Sawant;Venkataraman Jayanthi; World Journal of Gastroenterology 2012,

[2]

Effect of multispecies probiotics on irritable bowel syndrome: A randomized; double‐blind; placebo‐controlled trial[J] Jun Sik Yoon;Won Sohn;Oh Young Lee;Sang Pyo Lee;Kang Nyeong Lee;Dae Won Jun;Hang Lak Lee;Byung Chul Yoon;Ho Soon Choi;Won‐Seok Chung;Jae‐Gu Seo J Gastroenterol Hepatol 2014,

[3]

Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised; double-blind; placebo controlled trial[J] Luise Mølenberg Begtrup;Ove B Schaffalitzky de Muckadell;Jens Kjeldsen;René dePont Christensen;Dorte Ejg Jarbøl Scandinavian Journal of Gastroenterology 2013,

[4]

A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.[J] Roberts Lesley M;McCahon Deborah;Holder Roger;Wilson Sue;Hobbs F D Richard BMC gastroenterology 2013,

[5]

Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis[J] Rebecca M. Lovell;Alexander C. Ford Clinical Gastroenterology and Hepatology 2012,

[6]

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome[J] Wolfgang Kruis;Sigrun Chrubasik;Stephan Boehm;Christiane Stange;Juergen Schulze International Journal of Colorectal Disease 2012,

[7]

The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome: A Randomized; Double-blind; Placebo-controlled Trial[J] Bong Ki Cha;Seung Mun Jung;Chang Hwan Choi;In-Do Song;Hyun Woong Lee;Hyung Joon Kim;Jae Hyuk;Sae Kyung Chang;Kijeong Kim;Won-Seok Chung;Jae-Gu Seo Journal of Clinical Gastroenterology 2012,

[8]

Metabonomic Understanding of Probiotic Effects in Humans With Irritable Bowel Syndrome[J] Young-Shick Hong;Kyoung Sup Hong;Min-Hwa Park;Young-Tae Ahn;Jung-Hee Lee;Chul-Sung Huh;Jaekyung Lee;In-Kyoung Kim;Geum-Sook Hwang;Joo Sung Kim Journal of Clinical Gastroenterology 2011,

[9]

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind; placebo-controlled study.[J] Guglielmetti S;Mora D;Gschwender M;Popp K Alimentary pharmacology & therapeutics 2011,

[10]

A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial[J] Ligaarden Solveig ;Axelsson Lars;Naterstad Kristine;Lydersen Stian;Farup Per BMC Gastroenterology 2010,

← 1 2 →